The World Health Organization (WHO) Guideline Development Group recommended that patients with COVID-19 not receive the antibody drugs sotrovimab and casirivimab-imdevimab. The Group’s recommendation replaces previous conditional recommendations “Rapid Recommendations: A living WHO guideline on drugs for Covid-19,” published in The British Medical Journal two years ago, for the drugs’ use and is based on emerging evidence from laboratory studies that these drugs are not likely to work against currently circulating variants, such as omicron.
